logo-loader
RNS
viewOmega Diagnostics Group Plc

Investor results briefing

/**/ h1{margin-right:0cm;margin-left:0cm;text-align:justify;line-height:120%;font-size:10.0pt;font-family:"Verdana","sans-serif";color:#3B4FAE;}h2{margin-top:10.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:120%;font-size:13.0pt;font-family:"Cambria","serif";color:#4F81BD;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:12.0pt;margin-left:0cm;text-align:center;font-size:11.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .bb{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.bb{}p.cj{margin-top:0cm;margin-right:0cm;margin-bottom:12.0pt;margin-left:0cm;text-align:justify;line-height:120%;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: 1.35pt; margin-top: 0cm}p.ck{margin-top:0cm;margin-right:0cm;margin-bottom:12.0pt;margin-left:0cm;text-align:justify;line-height:120%;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: 1.35pt; margin-top: 0cm; text-align: center}span.cg{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.ce{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black;letter-spacing:-.4pt}p.cl{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.cc{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.cm{color:black}span.cn{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black} span.ca{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.co{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.cp{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.cq{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.cr{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.cs{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.ct{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.cu{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.cv{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.cw{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify} table.cx{width:478.8pt;margin-left:-7.1pt;border-collapse:collapse}tr.bt{height:6.85pt}td.bw{width:234.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.85pt}td.bu{width:222.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.85pt}p.cy{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: right}tr.bp{height:6.2pt}td.bs{width:234.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.2pt}p.cz{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}td.bq{width:222.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.2pt}span.br{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:windowtext;text-decoration: none} tr.bm{height:6.9pt}td.bo{width:234.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.9pt}td.bn{width:222.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.9pt}p.da{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}td.bl{width:316.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.9pt}td.bk{width:140.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:6.9pt}tr.bf{height:9.55pt}td.bj{width:234.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:9.55pt}td.bg{width:222.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:9.55pt}span.bi{font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext; text-decoration:none} span.bh{font-size: 11.0pt;font-family:"Calibri","sans-serif"}td.be{border:none}p.db{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.dc{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.dd{margin-top:0cm;margin-right:0cm;margin-bottom:12.0pt;margin-left:0cm;text-align:justify;line-height:120%;font-size:10.0pt;font-family:"Arial","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm} /**/
RNS Number : 0968U
Omega Diagnostics Group PLC
21 November 2019
 

 

Omega Diagnostics Group PLC

("Omega" or "the Company" or the "Group")

 

Investor results briefing

 

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces it will be hosting an investor evening for all investors on Wednesday 4 December 2019, accompanying the interim results for six months ended 30 September 2019.

 

The event will take place in the No.1 Cornhill, London, EC3V 3ND at 4.30pm for a 4.45pm start. This will be followed by light refreshments, and a chance to network.

 

The results presentation will be available on the Company website shortly after the event. No new information will be disclosed. 

 

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].

 

Contacts:

 

Omega Diagnostics Group PLC                         

Tel: 01259 763 030

Bill Rhodes, Interim Non-Executive Chairman

 

www.omegadiagnostics.com

Colin King, Chief Executive                             

 

Kieron Harbinson, Group Finance Director


                                                  


finnCap Ltd                                              

Tel: 020 7220 0500

Geoff Nash/James Thompson/Hannah Boros (Corporate Finance)


Camille Gochez (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRABXBDBGSDBGCG

Quick facts: Omega Diagnostics Group Plc

Price: 15.485

Market: AIM
Market Cap: £23.28 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE